Back to Search Start Over

The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes

Authors :
Caroline Buors
Mehdi Sakka
Christian Berthou
Eric Lippert
Isabelle Quintin-Roué
Gaelle Guillerm
Jean-Luc Carré
Jean-Richard Eveillard
Hélène Kerspern
Jean-Christophe Ianotto
Ahmed Meskar
Lenaïg Le Clech
Institut de cancérologie et d'hématologie
Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Services répartis, Architectures, MOdélisation, Validation, Administration des Réseaux (SAMOVAR)
Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP)
Centre National de la Recherche Scientifique (CNRS)
Département de Biochimie et de Pharmaco-Toxicologie (JHA)
Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato)
Lymphocyte B et Auto-immunité (LBAI)
Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM)
Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) (GGB)
Institut Brestois Santé Agro Matière (IBSAM)
Université de Brest (UBO)-Université de Brest (UBO)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)
Laboratoire d'hématologie (Labo Hémato - BREST)
CHRU Brest - Laboratoire d'Anatomo-Pathologie (CHU - AnaPath)
Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM)
Université de Brest (UBO)
Source :
Leukemia & lymphoma, Leukemia & lymphoma, Taylor & Francis, 2017, pp.1-6
Publication Year :
2017
Publisher :
HAL CCSD, 2017.

Abstract

International audience; Many case reports have indicated the occurrence of monoclonal gammopathy of uncertain significance (MGUS) or multiple myeloma (MM) in patients with Ph-negative myeloproliferative neoplasms (MPN), but few cohorts of patients have been published. This study concerns 667 patients newly diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET) who were tested for monoclonal (M) protein at diagnosis (13.9% of patients). The overall survival of patients with M protein was dramatically lower than that of patients without M protein (12.7 versus 22.4 years; p = .0132). Univariate analysis identified the presence of M protein as a potential risk factor for the secondary occurrence of myelofibrosis (p = .02), myelodysplastic syndrome (p = .043), and MM/Waldenstrom macroglobulinemia (p

Details

Language :
English
ISSN :
10428194 and 10292403
Database :
OpenAIRE
Journal :
Leukemia & lymphoma, Leukemia & lymphoma, Taylor & Francis, 2017, pp.1-6
Accession number :
edsair.doi.dedup.....f0dbf2f50304d6473b63a393ba9e44d9